Skip to main content
Top
Published in: The European Journal of Health Economics 8/2014

01-11-2014 | Original Paper

The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening

Authors: Pauline Chauvin, Jean-Michel Josselin, Denis Heresbach

Published in: The European Journal of Health Economics | Issue 8/2014

Login to get access

Abstract

When a cost-effectiveness analysis is implemented, the health-care system is usually assumed to adjust smoothly to the proposed new strategy. However, technological innovations in health care may often induce friction in the organization of care supply, implying the congestion of services and subsequent waiting times. Our objective here is to measure how these short run rigidities can challenge cost-effectiveness recommendations favorable to an innovative mass screening test for colorectal cancer. Using Markov modeling, we compare the standard Guaiac fecal occult blood test (gFOBT) with an innovative screening test for colorectal cancer, namely the immunological fecal occult blood test (iFOBT). Waiting time can occur between a positive screening test and the subsequent confirmation colonoscopy. Five scenarios are considered for iFOBT: no further waiting time compared with gFOBT, twice as much waiting time for a period of 5 or 10 years, and twice as much waiting time for a period of 5 or 10 years combined with a 25 % decrease in participation to confirmation colonoscopies. According to our modeling, compared with gFOBT, iFOBT would approximately double colonoscopy demand. Probabilistic sensitivity analysis enables concluding that the waiting time significantly increases the uncertainty surrounding recommendations favorable to iFOBT if it induces a decrease in the adherence rate for confirmation colonoscopy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adang, E.M.: Economic evaluation of innovative technologies in health care should include a short-run perspective. Eur. J. Health Econ. 9, 381–384 (2008)PubMedCrossRef Adang, E.M.: Economic evaluation of innovative technologies in health care should include a short-run perspective. Eur. J. Health Econ. 9, 381–384 (2008)PubMedCrossRef
2.
go back to reference Van de Wetering, G., Woertman, W.H., Adang, E.M.: Time to incorporate time in cost-effectiveness analysis. Eur. J. Health Econ. 13(3), 223–226 (2012)PubMedCrossRefPubMedCentral Van de Wetering, G., Woertman, W.H., Adang, E.M.: Time to incorporate time in cost-effectiveness analysis. Eur. J. Health Econ. 13(3), 223–226 (2012)PubMedCrossRefPubMedCentral
3.
go back to reference Van de Wetering, G., Woertman, W.H., Adang, E.M.: A model to correct for short-run inefficiencies in economic evaluation in healthcare. Health Econ. 21, 270–281 (2012)PubMedCrossRef Van de Wetering, G., Woertman, W.H., Adang, E.M.: A model to correct for short-run inefficiencies in economic evaluation in healthcare. Health Econ. 21, 270–281 (2012)PubMedCrossRef
4.
go back to reference Farnworth, M.G.: A game theoretic model of the relationship between prices and waiting times. J. Health Econ. 22(1), 47–60 (2003)PubMedCrossRef Farnworth, M.G.: A game theoretic model of the relationship between prices and waiting times. J. Health Econ. 22(1), 47–60 (2003)PubMedCrossRef
5.
go back to reference Johannesson, M., Johansson, P.O., Soderqvist, T.: Time spent on waiting lists for medical care: an insurance approach. J. Health Econ. 17(5), 627–644 (1998)PubMedCrossRef Johannesson, M., Johansson, P.O., Soderqvist, T.: Time spent on waiting lists for medical care: an insurance approach. J. Health Econ. 17(5), 627–644 (1998)PubMedCrossRef
6.
go back to reference Koopmanschap, M.A., Brouwer, W.B.F., Hakkaart-van Roijen, L., van Exel, N.J.A.: Influence of waiting time on cost-effectiveness. Soc. Sci. Med. 60(11), 2501–2504 (2005)PubMedCrossRef Koopmanschap, M.A., Brouwer, W.B.F., Hakkaart-van Roijen, L., van Exel, N.J.A.: Influence of waiting time on cost-effectiveness. Soc. Sci. Med. 60(11), 2501–2504 (2005)PubMedCrossRef
7.
go back to reference Sculpher, M., Fenwick, E., Claxton, K.: Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. PharmacoEconomics 17(5), 461–477 (2000)PubMedCrossRef Sculpher, M., Fenwick, E., Claxton, K.: Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. PharmacoEconomics 17(5), 461–477 (2000)PubMedCrossRef
8.
go back to reference Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., Boyle, P.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581–592 (2007)PubMedCrossRef Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., Boyle, P.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581–592 (2007)PubMedCrossRef
9.
go back to reference Kanavos, P., Schurer, W.: The dynamics of colorectal cancer management in 17 countries. Eur. J. Health Econ. 10(Suppl 1), 115–129 (2010)CrossRef Kanavos, P., Schurer, W.: The dynamics of colorectal cancer management in 17 countries. Eur. J. Health Econ. 10(Suppl 1), 115–129 (2010)CrossRef
10.
go back to reference Guittet, L., Bouvier, V., Mariotte, N., et al.: Comparison of a guaiac based and an immunochemical fecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56, 210–214 (2007)PubMedCrossRefPubMedCentral Guittet, L., Bouvier, V., Mariotte, N., et al.: Comparison of a guaiac based and an immunochemical fecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56, 210–214 (2007)PubMedCrossRefPubMedCentral
11.
go back to reference Boncz, I., Brodszky, V., Péntek, M., et al.: The disease burden of colorectal cancer in Hungary. Eur. J. Health Econ. 10(Suppl 1), 35–40 (2010)CrossRef Boncz, I., Brodszky, V., Péntek, M., et al.: The disease burden of colorectal cancer in Hungary. Eur. J. Health Econ. 10(Suppl 1), 35–40 (2010)CrossRef
12.
go back to reference Schurer, W.: The status of colorectal cancer care in the Netherlands: past, present and future. Eur. J. Health Econ. 10(suppl 1), S51–S56 (2010)PubMedCrossRef Schurer, W.: The status of colorectal cancer care in the Netherlands: past, present and future. Eur. J. Health Econ. 10(suppl 1), S51–S56 (2010)PubMedCrossRef
13.
go back to reference Berchi, C., Bouvier, V., Réaud, J.M., et al.: Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 13, 227–238 (2004)PubMedCrossRef Berchi, C., Bouvier, V., Réaud, J.M., et al.: Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 13, 227–238 (2004)PubMedCrossRef
14.
go back to reference Lejeune, C., Dancourt, V., Arveux, P., Bonithon-Kopp, C., Faivre, J.: Cost effectiveness analysis of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int. J. Technol. Assess. Health Care 26, 40–47 (2010)PubMedCrossRef Lejeune, C., Dancourt, V., Arveux, P., Bonithon-Kopp, C., Faivre, J.: Cost effectiveness analysis of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int. J. Technol. Assess. Health Care 26, 40–47 (2010)PubMedCrossRef
15.
go back to reference Chauvin, P., Josselin, J.M., Heresbach, D.: Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer. Eur. J. Health Econ. 13(3), 237–250 (2012)PubMedCrossRef Chauvin, P., Josselin, J.M., Heresbach, D.: Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer. Eur. J. Health Econ. 13(3), 237–250 (2012)PubMedCrossRef
16.
go back to reference Schurer, W., Kanavos, P.: Colorectal cancer management in the United Kingdom: current practice and challenges. Eur. J. Health Econ. 10(Suppl 1), 85–90 (2010)CrossRef Schurer, W., Kanavos, P.: Colorectal cancer management in the United Kingdom: current practice and challenges. Eur. J. Health Econ. 10(Suppl 1), 85–90 (2010)CrossRef
17.
go back to reference Vrangbaek, K., Nielsen, M.: Colorectal cancer in Denmark: status and dilemmas. Eur. J. Health Econ. 10(suppl 1), S5–S13 (2010)PubMedCrossRef Vrangbaek, K., Nielsen, M.: Colorectal cancer in Denmark: status and dilemmas. Eur. J. Health Econ. 10(suppl 1), S5–S13 (2010)PubMedCrossRef
18.
go back to reference Berg, B., Denton, B., Nelson, H., Balasubramanian, H., Rahman, A., Bailey, A., Lindor, K.: A discrete event simulation model to evaluate operational performance of a colonoscopy suite. Med. Decis. Making 30(3), 380–387 (2010)PubMedCrossRef Berg, B., Denton, B., Nelson, H., Balasubramanian, H., Rahman, A., Bailey, A., Lindor, K.: A discrete event simulation model to evaluate operational performance of a colonoscopy suite. Med. Decis. Making 30(3), 380–387 (2010)PubMedCrossRef
19.
go back to reference Wilschut, J.A., Habbema, J.D., van Leerdam, M.E., Hol, L., Lansdorp-Vogelaar, I., Kuipers, E.J., van Ballegooijen, M.: Fecal occult blood testing when colonoscopy capacity is limited. J. Natl. Cancer Inst. 103(23), 1741–1751 (2011)PubMedCrossRef Wilschut, J.A., Habbema, J.D., van Leerdam, M.E., Hol, L., Lansdorp-Vogelaar, I., Kuipers, E.J., van Ballegooijen, M.: Fecal occult blood testing when colonoscopy capacity is limited. J. Natl. Cancer Inst. 103(23), 1741–1751 (2011)PubMedCrossRef
20.
go back to reference Manfredi, S., Piette, C., Durand, G., et al.: Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance. Endoscopy 40(5), 422–427 (2008)PubMedCrossRef Manfredi, S., Piette, C., Durand, G., et al.: Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance. Endoscopy 40(5), 422–427 (2008)PubMedCrossRef
23.
go back to reference Goulard, H., Boussac-Zarebska, M., Bloch, J.: Epidemiological assessment of the pilot programme for organized colorectal cancer screening, France, 2007. Bulletin épidémiologique hebdomadaire. INVS 2–3, 22–25 (2009) Goulard, H., Boussac-Zarebska, M., Bloch, J.: Epidemiological assessment of the pilot programme for organized colorectal cancer screening, France, 2007. Bulletin épidémiologique hebdomadaire. INVS 2–3, 22–25 (2009)
25.
go back to reference Clerc, L., Jooste, J., Lejeune, C., et al.: Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur. J. Health Econ. 9, 361–367 (2008)PubMedCrossRef Clerc, L., Jooste, J., Lejeune, C., et al.: Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur. J. Health Econ. 9, 361–367 (2008)PubMedCrossRef
26.
go back to reference Zauber, A.G., Lansdop-Vogelaar, I., Knudsen, A.B., et al.: Evaluating test strategies for colorectal cancer screening. Ann. Intern. Med. 149, 659–669 (2008)PubMedCrossRefPubMedCentral Zauber, A.G., Lansdop-Vogelaar, I., Knudsen, A.B., et al.: Evaluating test strategies for colorectal cancer screening. Ann. Intern. Med. 149, 659–669 (2008)PubMedCrossRefPubMedCentral
27.
go back to reference Van Rijn, J., Reitsma, J.B., Stoker, J., et al.: Polyp miss rate determined by tandem colonoscopy: a systematic review. Am. J. Gastroenterol. 101, 343–350 (2006)PubMedCrossRef Van Rijn, J., Reitsma, J.B., Stoker, J., et al.: Polyp miss rate determined by tandem colonoscopy: a systematic review. Am. J. Gastroenterol. 101, 343–350 (2006)PubMedCrossRef
28.
go back to reference Denis, B., Ruetsch, M., Strentz, P., et al.: Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 56, 1579–1584 (2007)PubMedCrossRefPubMedCentral Denis, B., Ruetsch, M., Strentz, P., et al.: Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 56, 1579–1584 (2007)PubMedCrossRefPubMedCentral
29.
30.
go back to reference Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 5, 479–500 (2000)CrossRef Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 5, 479–500 (2000)CrossRef
31.
go back to reference Barton, G.R., Briggs, A.H., Fenwick, E.A.L.: Optimal cost-effectiveness decisions: the Role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11, 886–897 (2008)PubMedCrossRef Barton, G.R., Briggs, A.H., Fenwick, E.A.L.: Optimal cost-effectiveness decisions: the Role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11, 886–897 (2008)PubMedCrossRef
32.
go back to reference Faivre, J., Dancourt, V., Lejeune, C., et al.: Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126, 1674–1680 (2004)PubMedCrossRef Faivre, J., Dancourt, V., Lejeune, C., et al.: Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126, 1674–1680 (2004)PubMedCrossRef
33.
34.
go back to reference Regula, J., Rupinski, M., Kraszewska, M., et al.: Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 355, 1863–1872 (2006)PubMedCrossRef Regula, J., Rupinski, M., Kraszewska, M., et al.: Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 355, 1863–1872 (2006)PubMedCrossRef
35.
go back to reference Yamaji, Y., Mitsushima, T., Ikuma, H., et al.: Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese. Gut 53, 568–572 (2004)PubMedCrossRefPubMedCentral Yamaji, Y., Mitsushima, T., Ikuma, H., et al.: Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese. Gut 53, 568–572 (2004)PubMedCrossRefPubMedCentral
36.
go back to reference Church, J.: Clinical significance of the small colorectal polyps. Dis. Colon Rectum 47, 481–485 (2004)PubMedCrossRef Church, J.: Clinical significance of the small colorectal polyps. Dis. Colon Rectum 47, 481–485 (2004)PubMedCrossRef
37.
go back to reference Pickhardt, P.J., Hassan, C., Laghi, A., et al.: Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions. Cancer 109, 2213–2221 (2007)PubMedCrossRef Pickhardt, P.J., Hassan, C., Laghi, A., et al.: Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions. Cancer 109, 2213–2221 (2007)PubMedCrossRef
38.
go back to reference Hur, C., Chung, D.C., Schoen, R.E., Gazelle, G.S.: The management of small polyps found by virtual colonoscopy: results of a decision analysis. Clin. Gastroenterol. Hepatol. 5, 237–244 (2007)PubMedCrossRef Hur, C., Chung, D.C., Schoen, R.E., Gazelle, G.S.: The management of small polyps found by virtual colonoscopy: results of a decision analysis. Clin. Gastroenterol. Hepatol. 5, 237–244 (2007)PubMedCrossRef
39.
go back to reference Brenner, H., Hoffmeister, M., Stegmaier, C., et al.: Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut 56, 1585–1589 (2007)PubMedCrossRefPubMedCentral Brenner, H., Hoffmeister, M., Stegmaier, C., et al.: Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut 56, 1585–1589 (2007)PubMedCrossRefPubMedCentral
Metadata
Title
The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening
Authors
Pauline Chauvin
Jean-Michel Josselin
Denis Heresbach
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 8/2014
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-013-0525-9

Other articles of this Issue 8/2014

The European Journal of Health Economics 8/2014 Go to the issue